Allovir Valuation
| ALVR Stock | USD 9.80 0.29 3.05% |
At this time, the firm appears to be overvalued. Allovir shows a prevailing Real Value of $4.91 per share. The current price of the firm is $9.8. Our model approximates the value of Allovir from analyzing the firm fundamentals such as Return On Equity of -0.8, shares owned by insiders of 49.11 %, and Current Valuation of (71.23 M) as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Allovir's valuation include:
Overvalued
Today
Please note that Allovir's price fluctuation is unstable at this time. Calculation of the real value of Allovir is based on 3 months time horizon. Increasing Allovir's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Allovir stock is determined by what a typical buyer is willing to pay for full or partial control of Allovir. Since Allovir is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Allovir Stock. However, Allovir's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 9.8 | Real 4.91 | Target 1.2 | Hype 9.86 | Naive 9.41 |
The intrinsic value of Allovir's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Allovir's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Allovir helps investors to forecast how Allovir stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Allovir more accurately as focusing exclusively on Allovir's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Allovir's intrinsic value based on its ongoing forecasts of Allovir's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Allovir's closest peers.
Allovir Cash |
|
Allovir Valuation Trend
Allovir's real value is important for investors to make better decisions and a more accurate overall view of Allovir's financial worth over time. Using both Allovir's enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Allovir Total Value Analysis
Allovir is presently anticipated to have valuation of (71.23 M) with market capitalization of 85.25 M, debt of 27.43 M, and cash on hands of 172.67 M. The negative valuation of Allovir may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Allovir fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(71.23 M) | 85.25 M | 27.43 M | 172.67 M |
Allovir Asset Utilization
One of the ways to look at asset utilization of Allovir is to check how much profit was generated for every dollar of assets it reports. Allovir shows a negative utilization of assets of -0.37 percent, losing $0.003653 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Allovir shows how discouraging it operates for each dollar spent on its assets.Allovir Ownership Allocation
Allovir holds a total of 115.36 Million outstanding shares. Allovir retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Allovir Profitability Analysis
Net Loss for the year was (190.42 M) with profit before overhead, payroll, taxes, and interest of 165 K.About Allovir Valuation
The stock valuation mechanism determines Allovir's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Allovir based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Allovir. We calculate exposure to Allovir's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Allovir's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -358.2 K | -376.1 K | |
| Pretax Profit Margin | (166.15) | (157.84) | |
| Operating Profit Margin | (186.10) | (176.79) | |
| Net Loss | (151.76) | (144.17) |
Allovir Growth Indicators
Investing in growth stocks can be very risky. If the company such as Allovir does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 104.1 M |
Allovir Current Valuation Indicators
Allovir's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Allovir's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Allovir, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Allovir's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Allovir's worth.Additional Tools for Allovir Stock Analysis
When running Allovir's price analysis, check to measure Allovir's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allovir is operating at the current time. Most of Allovir's value examination focuses on studying past and present price action to predict the probability of Allovir's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allovir's price. Additionally, you may evaluate how the addition of Allovir to your portfolios can decrease your overall portfolio volatility.